Best Regenerative Medicine Companies in United States
The 139 best Regenerative Medicine companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Humacyte.
Ranking the best Regenerative Medicine companies in the United States by disclosed equity funding, this directory tracks 139 ventures that have collectively raised $2.7 billion, with not a single unicorn in the mix yet. That last part tells you something. Arsenal Medical leads the field at $70 million raised, followed by Stellular Bio and Epibone at $44 million each, and Healionics at $27 million. The funding is real and it's patient, sourced heavily from HHS, NIH, and America's Seed Fund rather than venture megafunds chasing quick exits. The global market stood at $10.1 billion in 2020 and is forecast to reach $83.2 billion by 2030 at a 21.1% CAGR, driven by chronic disease prevalence and cancer treatment demand. So the capital base here, $2.7 billion across 139 companies, is still early relative to where this sector is heading.
What I'd watch is the regulatory friction. The lack of standardized approval pathways for regenerative drugs remains a structural drag on commercialization timelines, even as hot themes like cell-based therapies and machine learning drug discovery accelerate R&D. Coverage of the space is rising fast, with frontiers in healthcare regenerative medicine drawing wider attention from clinicians and investors alike. The companies in this directory aren't chasing hype. They're building on validated science, grant capital, and a market trajectory that's hard to argue with.
Ranked: Best Regenerative Medicine companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Humacyte Provider of human tissue-based products for vascular disease | $425M | 62 mo ago | 70 70 → 166 (+137%) · sector median +11% | 2004 | Juliana Blum Co-Founder | 13 signals Earnings · Funding · Capital raise | 137 patents Engineered vascular grafts and medicated implantable matrices for blood vessel replacement. | — |
| 2 | MiMedx Group Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | $213M | 71 mo ago | 735 735 → 789 (+7%) · sector median +11% | 1985 | — | 6 signals ▼40% Earnings · Leadership | 472 patents Placental-derived collagen wound healing matrices and grafts for tissue repair | 1 launch |
| 3 | Ensoma Developer of in vivo hematopoietic stem cell engineering for genomic medicine | $205M | 37 mo ago | 52 52 → 51 (-2%) · sector median +11% | 2019 | — | — | 62 patents Adenoviral gene‑therapy vectors enabling multi‑lineage therapeutic expression and stem‑cell mobilization | — |
| 4 | Walking Fish Therapeutics Developer of cell-based therapeutic solutions for treating cancer & immunological disorders | $123M | 52 mo ago | 37 | 2019 | Seenu Kothakota Co-Founder | — | — | — |
| 5 | Histogenics Developer of restorative cell therapies for orthopedic diseases | $116M | 117 mo ago | 84 | 2000 | — | — | 121 patents Adhesive scaffolds and porous matrices for articular cartilage regeneration. | — |
| 6 | BioTissue Developer of regenerative biologic therapies for eye care | $110M | 60 mo ago | 234 234 → 372 (+59%) · sector median +11% | 2001 | Amy Tseng Founder and Board Member | — | 31 patents Patents concentrated in health & consumer products | 1 job opening |
| 7 | Satellite Bio Developer of proprietary implantable satellite organs | $110M | 51 mo ago | 21 21 → 24 (+14%) · sector median +11% | 2019 | Arnav Chhabra Co-Founder | — | — | — |
| 8 | AxoGen Developer of therapies for the repair of peripheral nerve injuries | $96M | 115 mo ago | 809 809 → 607 (-25%) · sector median +11% | 2002 | Karen Zaderej President | 13 signals ▼32% Earnings · IPO · Acquisition | 560 patents Peripheral nerve repair and regeneration using specialized biomaterial grafts and protective devices | — |
| 9 | Cerapedics Developer of Osteobiologic products | $88M | 95 mo ago | 3 | 1996 | Valeska Schroeder CEO | — | 49 patents Bioactive peptide-coated calcium‑phosphate coatings for orthopedic implants reducing inflammation | 1 launch |
| 10 | Arsenal Medical Developer of polymer-based foams and fibers 45Funding top 20%Talent top 23%Product top 26%Moat top 26% All 10 signals ▾Fundingtop 20% Talenttop 23% Producttop 26% Moattop 26% Patentstop 27% Innovationtop 35% Techbottom 39% Globalbottom 38% Marketbottom 26% Newsbottom 22% Funding: Raised $69.9M across 21 rounds · 21 rounds over 21 yrs (1.0/yr) Talent: 5 named leaders on record · 5 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $70M | 10 mo ago | 16 16 → 29 (+81%) · sector median +11% | 2005 | Eric Stern Co-Founder & CTO | — | 190 patents Hemostatic and embolic biomaterial devices for bleeding control and vascular occlusion. | — |
| 11 | CorMatrix Cardiovascular regeneration leader, healing hearts with innovative solutions | $55M | 58 mo ago | 50 | 2001 | — | — | — | — |
| 12 | Augmenix Provider of a hydrogel spacer for prostate cancer radiation therapy | $47M | 119 mo ago | 153 153 → 100 (-35%) · sector median +11% | 2008 | — | — | — | — |
| 13 | LoneStar Heart Cardiac therapies for patients with Chronic Heart Failure | $45M | 110 mo ago | 2 | 2010 | Frank Ahmann CEO & President | — | — | — |
| 14 | LifeSprout Developing revolutionary products for aesthetic and regenerative medicine | $45M | 74 mo ago | 12 12 → 20 (+67%) · sector median +11% | 2015 | Justin Sacks Co-Founder | — | 14 patents Collagen‑hydrogel composites for soft‑tissue augmentation and fat grafting applications | — |
| 15 | Stellular Bio Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells 37Funding top 28%Talent top 28%Moat bottom 38%Global bottom 37% All 5 signals ▾Fundingtop 28% Talenttop 28% Moatbottom 38% Globalbottom 37% Marketbottom 32% Funding: Raised $44.5M across 9 rounds · 9 rounds over 10 yrs (0.9/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 37/100 | $44M | 4 mo ago | 12 | 2014 | Joseph Italiano Co-Founder | — | — | — |
| 16 | Epibone Developer of patient‑specific bone and cartilage grafts 50Moat top 25%Talent top 28%Funding top 29%Patents top 32% All 9 signals ▾Moattop 25% Talenttop 28% Fundingtop 29% Patentstop 32% Innovationtop 38% Techtop 46% Globalbottom 42% Marketbottom 31% Newsbottom 21% Moat: Editorial + unicorn rating 7/10 · IP moat: 48 patents Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $44M | 9 mo ago | 34 | 2013 | Elisa Cimetta Co-Founder | — | 48 patents Regenerative orthopedic biomaterials for injectable cartilage/tendon/ligament repair and surgical tools. | — |
| 17 | Carbylan Therapeutics using polymers of hyaluronic acid for pain management. | $43M | 135 mo ago | 7 | 2004 | — | — | — | — |
| 18 | PolarityTE Developer of regenerative medicine | $42M | 25 mo ago | 37 | 1998 | — | — | 63 patents Patents concentrated in chemistry & materials | — |
| 19 | Imagine Pharma Developing polypeptide therapeutic drugs for treating cardiovacular disorders | $40M | 31 mo ago | 12 | 2016 | — | — | — | — |
| 20 | Tepha Global medical technology company advancing healthcare through innovative solutions and services | $40M | 171 mo ago | 51 | 1998 | — | — | 627 patents Resorbable polymer medical implants and devices for surgery and aesthetic reconstruction | — |
| 21 | Solsys Medical Provider of human skin allograft and dressing for wound care | $37M | 103 mo ago | 80 | 1999 | Guy Levy Co-Founder & CSO | — | — | — |
| 22 | Embody Provider of collagen-based regenerative matrices for soft tissue repair | $36M | 45 mo ago | 25 | 2014 | Michael Francis Co-Founder | — | 133 patents Advanced collagen-based scaffolds and delivery devices for surgical implants and tissue engineering | — |
| 23 | Triad Life Sciences Developer of regenerative medicine technologies | $32M | 57 mo ago | 33 | 2017 | — | — | — | — |
| 24 | Organogenesis Regenerative tissue innovations for advanced wound care and surgical solutions | $30M | 19 mo ago | 856 856 → 921 (+8%) · sector median +11% | 1985 | Gary Gillheeney CEO | 7 signals ▼73% Earnings | 209 patents Collagen-based biomaterials for wound healing, tissue regeneration, and anti‑inflammatory assay kits. | — |
| 25 | Healionics Manufacturer of synthetic biomaterials and implantable medical devices 27Talent top 15%Moat top 25%Funding top 35%Patents top 42% All 9 signals ▾Talenttop 15% Moattop 25% Fundingtop 35% Patentstop 42% Innovationbottom 47% Globalbottom 40% Techbottom 32% Marketbottom 20% Newsbottom 18% Talent: Analyst team rating 5/5 Moat: Editorial + unicorn rating 7/10 · IP moat: 42 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $27M | 6 mo ago | 10 | 2007 | — | — | 42 patents Implantable vascular grafts and porous ocular drug‑delivery devices for eye disease treatment | — |
| 26 | RevBio Developer of synthetic adhesive used for bone/dental repair 57Talent top 23%Innovation top 28%Patents top 28%Funding top 34% All 7 signals ▾Talenttop 23% Innovationtop 28% Patentstop 28% Fundingtop 34% Moattop 38% Marketbottom 37% Globalbottom 31% Talent: 5 named leaders on record · 5 C-suite/founder profiles curated Innovation: 50 patents (top 31% of patent-holders) · 44 filings since 2022 vs 6 in 2017-21 rank vs industry peers · Fliar Intelligence Index 57/100 | $24M | 12 mo ago | 29 | 2014 | Michael Brown Co-Founder | — | 50 patents Biomedical adhesives and bone fixation devices for controlled drug delivery | — |
| 27 | Artelon Developer of regenerative medicine for the soft tendon ligament reconstruction | $20M | 36 mo ago | 72 | 1986 | Lars Peterson Founder | — | — | — |
| 28 | Carmell Biotech company specializing in the development of plasma-based bioactive materials for tissue repair. | $20M | 71 mo ago | 7 | 2007 | Rajiv Shukla CEO | — | 2 patents Plasma-assisted synthesis of specialty plastics and biodegradable polymers | — |
| 29 | Royal Biologics Innovating orthobiologics and wound care solutions for enhanced healing | $20M | 16 mo ago | 16 | 2015 | Salvatore Leo CEO | — | 14 patents Autologous bone graft enhancement and marrow-derived cell/fluid separation technologies. | 2 launchs |
| 30 | Sofregen Natural biomaterials for soft tissue regeneration in aesthetic and surgical procedures | $19M | 81 mo ago | 8 | 2014 | Anh Hoang Co-Founder & CSO | — | — | — |
| 31 | Vascudyne Developer of regenerative biomaterials for tissue repair and replacement | $18M | 13 mo ago | 6 | 2014 | Jeff Franco Co-Founder | — | 40 patents Engineered tissue implants for cardiovascular valves, grafts, and nerve repair | 1 award |
| 32 | Dimension Inx Provider of 3D bio materials for regenerative medicine | $18M | 40 mo ago | 27 | 2017 | Ramille Shah Co-Founder & CSO | — | 12 patents 3D-printed self-gelling biomaterials for implantable cell-encapsulation devices. | 1 internship |
| 33 | GeniPhys Developer of collagen polymers for tissue regeneration | $10M | 4 mo ago | 4 | 2014 | — | — | 18 patents Collagen-based biologic fillers for tissue regeneration and high-strength matrix scaffolds. | — |
| 34 | Gel4Med Bioinspired medical solutions company developing advanced biomaterials for unmet clinical needs | $10M | 14 mo ago | 4 | 2015 | — | — | 40 patents Peptide-based self‑assembling hydrogels for regenerative medicine and targeted drug/cell delivery | 1 partnership |
| 35 | Ventrix Developer of extracellular matrix-based therapeutics for cardiac diseases | $6M | 33 mo ago | 2 | 2009 | Karen Christman Co-Founder | — | 18 patents Cardiac therapeutic compositions and delivery methods for heart disease treatment | — |
| 36 | Jellatech Provider of animal-free collagen and gelatin products for multiple industries | $6M | 33 mo ago | 7 | 2020 | Stephanie Michelsen Co-Founder & CEO | — | 10 patents Cell‑cultured collagen/gelatin production for biomedical and cosmetic material manufacturing. | — |
| 37 | Halo Biosciences Developer of therapies by editing extracellular matrix | $5M | 14 mo ago | 12 | 2019 | Andy Wardle Co-Founder & Advisor | — | — | — |
| 38 | BioDevek Developer of next generation of surgical sealant solutions | $5M | 10 mo ago | 3 | 2014 | Elazer Edelman Co-Founder | — | 15 patents Biocompatible medical adhesives for tissue bonding and wound closure | — |
| 39 | GelSana Developer of novel hydrogels for wound healing | $4M | 11 mo ago | 2 | 2020 | Melissa Krebs Founder & CEO | — | — | 1 partnership |
| 40 | Inovedis Developer of surgical implants for tendon healing | $4M | 32 mo ago | — | 2019 | Stefan Welte Co-Founder & Co-CEO | — | — | — |
| 41 | Lynch Biologics Developer of regenerative medicines for orthopaedic, periodontal and oral treatments | $4M | 29 mo ago | 9 | 2015 | Sam Lynch Founder & CEO | — | — | — |
| 42 | Bluegrass Advanced Materials Antioxidant polymers based therapy for the treatment of oral mucositis | $4M | 14 mo ago | 2 | 2013 | Thomas Dziubla Co-Founder | — | — | — |
| 43 | inSoma Bio Provider of protein-based biomaterials for tissue engineering and regenerative medicine | $3M | 6 mo ago | 6 | 2018 | Stefan Roberts Co-Founder & CEO | — | — | — |
| 44 | Deverra Therapeutics Provider of progenitor blood and immune cells for clinical application | $2M | 33 mo ago | 13 | 2020 | Colleen Delaney Founder | — | — | — |
| 45 | BioStem Technologies Provider of placental-based amniotic tissue products | $2M | 31 mo ago | 10 | 2006 | Andrew VanVurst Co-Founder | 9 signals ▼36% Earnings · Leadership · Acquisition | 7 patents Regenerative biomaterials from human umbilical cord and placental tissue for therapeutic applications | — |
| 46 | Chromocell Uses rare cells suited for effective high-throughput screening | $950K | 22 mo ago | 4 | 2002 | Christian Kopfli CEO | — | 318 patents Fluorogenic oligo cell‑engineering assays and sweet‑taste/sodium‑channel therapeutic modulators | — |
| 47 | TYBR Health Provider of regenrative medicine for post surgical scarring | $835K | 17 mo ago | 7 | 2020 | Alex Smith Co-Founder | — | — | 1 launch |
| 48 | LambdaVision Provider of a protein-based retinal prosthesis for retinal degenerative diseases | $650K | 7 mo ago | 7 | 2009 | — | — | 6 patents Retinal cell stimulation therapies for vision restoration | 1 partnership |
| 49 | PRO Therapeutics Developer of regenerative medicine for orthopedic diseases | $477K | 6 mo ago | — | 2023 | Julie Lenzer CEO | — | — | — |
| 50 | Plakous Therapeutics Developer of regenerative therapies from the placenta | $310K | 16 mo ago | 6 | 2016 | Seth Tomblyn Co-Founder | — | — | — |
Top 12 Regenerative Medicine companies in United States
#1
Series A · Watertown, Massachusetts · founded 2014 · 12 employees$44.5Mraised▾
Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells. It offers programmable logic controller platform focused on modifying the regenerative power of platelets, enabling researchers to create reengineering cell therapies.
- Jan 2026Series A—
- Mar 2025Grant (prize money)$356.5K
- Aug 2019Series A$26.4M
- May 2017Series A$10M
#2
Series C · Seattle, Washington · founded 2007 · 10 employees$26.6Mraised▾
Healionics is a manufacturer of synthetic biomaterials and implantable medical devices. It provides tissue regeneration and device bio integration solutions to medical device manufacturers. It offers sphere-templated angiogenic regeneration (STAR) technology, which provides substrate independent, precision-engineered, and 3D biomaterial scaffolds that enhance the bio-integration and promote healing of implanted medical devices. The company’s products are used in various areas, including wound care, aesthetic medicine, cardiovascular surgery, diabetes, general surgery, ophthalmology, pain management, regenerative medicine, and urological/women's health.
- Dec 2025Series C$2M
- Apr 2024Grant (prize money)$953.4K
- Oct 2023Series C$5.5M
- May 2021Series C$5.5M
#3
Series D · Waltham, Massachusetts · founded 2005 · 16 employees$69.9Mraised▾
Arsenal Medical is developing polymer-based foams and fibers. The company is developing a system that injects an in-situ curing elastomeric polymer material that fills and seals the aneurysm sac around a stent-graft.
- Jul 2025Grant (prize money)$314.4K
- May 2021Grant (prize money)$1.9M
- Jul 2020Grant (prize money)$367.2K
- Jun 2019Series D$6M
#4
Series A · Zionsville, Indiana · founded 2014 · 4 employees$10.5Mraised▾
Developer of collagen polymers for tissue regeneration. It offers Collymer a polymerizable scaffold-forming collagen that supports tissue restoration and regeneration. It is used in cartilage replacement, vascular grafts, and heart valve replacement, and others.
- Jan 2026Series A$3M
- Oct 2024Grant (prize money)$500K
- Mar 2023Series A$6M
- Nov 2022Series A$4.5M
#5
Series B · Brooklyn, New York · founded 2013 · 34 employees$44.3Mraised▾
Developer of patient‑specific bone and cartilage grafts. The company is offering custom‑shaped, living bone grafts engineered from a patient’s adipose‑derived mesenchymal stem cells and a CT scan of the defect. These are intended for complex bone‑reconstruction cases such as facial, craniofacial, or other skeletal defects.
- Sep 2025Series B$4.3M
- Nov 2024Series B—
- Dec 2022Series B$18.5M
- Nov 2021Series B$1M
#6
Series B · Lowell, Massachusetts · founded 2014 · 29 employees$24.4Mraised▾
Developer of synthetic adhesive used for bone/dental repair. The company's proprietary technology includes Tetranite that is a bio-engineered protein derived from worms. The company's product can be used in implant stabilization, fracture repair, spine fusion, dental bone grafting, joint reconstruction, and cranial flap fixation.
- May 2025Grant (prize money)$2M
- Sep 2024Grant (prize money)$1.7M
- Oct 2023Grant (prize money)—
- Sep 2023Grant (prize money)$3M
#7
Seed · Durham, North Carolina · founded 2018 · 6 employees$2.8Mraised▾
Provider of protein-based biomaterials for tissue engineering and regenerative medicine. The company offers genetically engineer protein-based materials that can mimic the naturally found elastin found in extracellular. The company's proprietary protein biomatrices known as Fractomers contain bio-active sequences that are thermo-responsive.
- Nov 2025Grant (prize money)$2M
- Sep 2025Seed$1.9M
- Sep 2024Grant (prize money)$294K
- Aug 2024Grant (prize money)$296.2K
#8
Series A · Stillwater, Minnesota · founded 2014 · 6 employees$17.7Mraised▾
Developer of regenerative biomaterials for tissue repair and replacement. The company uses a proprietary Tissue technology platform to develop soft tissue implants and medical devices such as vascular graft for hemodialysis access.
- May 2025Grant (prize money)—
- Oct 2021Series A$17.7M
#9
Funding Raised · Boston, Massachusetts · founded 2014 · 3 employees$4.6Mraised▾
Developer of next generation of surgical sealant solutions. The company uses a biodegradable and biocompatible adhesive material platform to develop surgical sealants. It is used to prevent leakage of body fluids from the suture line, such as blood following vascular surgeries and other minimally invasive surgeries.
- Aug 2025Grant (prize money)$2.1M
- Apr 2025Grant (prize money)$1.2M
- Jun 2024Grant (prize money)$978K
- Dec 2023Grant (prize money)$275K
#10
Funding Raised · Boston, Massachusetts · founded 2015 · 4 employees$10.1Mraised▾
Bioinspired medical solutions company developing advanced biomaterials for unmet clinical needs. This is a commercial-stage company focused on shaping the future of medicine by harnessing the power of smart materials to address significant medical challenges. Utilizing bioinspiration and materials engineering, the company has developed a Smart Materials Platform for creating therapeutics and devices. Their lead asset targets wound care and surgical reconstruction. Committed to enhancing health outcomes and access for all patients, they develop novel biomaterials. The proprietary Smart Materials Platform is an innovative bioengineering approach for addressing a wide range of clinical needs. They collaborate and innovate around novel treatments. The company focuses on research and development to create advanced medical solutions.
- Apr 2025Grant (prize money)$1.2M
- Sep 2023Grant (prize money)$2.6M
- Aug 2020Grant (prize money)$300K
- Jul 2020Grant (prize money)$409.7K
#11
Series A · Aurora, Colorado · founded 2020 · 2 employees$4.2Mraised▾
Developer of novel hydrogels for wound healing. The company has developed the first bio-inert adhesive hydrogel delivery system that offers controlled delivery of therapeutics to promote healing and accelerate wound closure while avoiding unwanted inflammatory responses.
- Jul 2025Grant (prize money)$299.6K
- Sep 2024Grant (prize money)$325K
- Nov 2023Series A$3.5M
- Apr 2023Grant (prize money)$299.6K
#12
Public · Canton, Massachusetts · founded 1985 · 856 employees$30Mraised▾
Regenerative tissue innovations for advanced wound care and surgical solutions. We are dedicated to empowering healing through regenerative medicine. Our focus lies in delivering clinicians a comprehensive range of regenerative tissue innovations and essential services. We specialize in advanced wound care and surgical & sports medicine solutions. We are committed to elevating the standard of care by providing transformative solutions. Our offerings include products like PuraPly and Affinity, alongside patient and provider support programs. We focus on innovation and regenerative solutions. We provide resources and support to healthcare professionals, ensuring they have access to the most advanced regenerative solutions available. We are committed to corporate social responsibility, ethics, and quality systems.
- Nov 2024Post IPO$130M
- May 2017Conventional Debt$20M
- Apr 2016Series C$30M
- Jan 2009Grant (prize money)$7.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Regenerative Medicine coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth flat
How research on Regenerative Medicine is moving in the United States
A read on the academic research around Regenerative Medicine — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 10,806 United States-affiliated papers.
- Harvard University661
- Brigham and Women's Hospital303
- Stanford University282
- Heidelberg University240
- Johns Hopkins University233
- Organoid21→1370
- Tissue engineering136→715
- Cell biology64→599
- Self-healing hydrogels69→439
- Induced pluripotent stem cell40→392
- Organoid10→984
- Tissue engineering199→947
- Regeneration (biology)66→544
- Stem cell92→524
- Biomedical engineering87→513
- Organoid2→226
- Tissue engineering96→275
- Regeneration (biology)35→214
- Stem cell42→210
- Induced pluripotent stem cell11→108
Where regenerative medicine is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing regenerative medicine patents in the United States
United States regenerative medicine patent filing is accelerating — 1,261 filings from 739 assignees (2016–2025), led by Childrens Hospital MED CT, UNIV WAKE Forest Health Sciences, BIO2 Technologies; annual filings 63→189.
- Childrens Hospital MED CT138
- UNIV WAKE Forest Health Sciences62
- BIO2 Technologies53
- UNIV Columbia44
- UNIV California44
- UNIV Leland Stanford Junior42
- UNIV Rutgers40
- UNIV RICE William M37
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.